新警察故事

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

笑傲江湖

A | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。　　讯 8月14日，河南省政府新闻办召开河南省开展生态环境法典涉及地方性法规清理工作新闻发布会。　　会上，河南省人大法制委员会副主任委员李哲介绍，《中华人民共和国生态环境法典》是继《中华人民共和国民法典》之后，我国第二部以“法典”命名的法律。生态环境法典对于加快推进人与自然和谐共生的现代化，实现中华民族永续发展具有重大而深远的意义。开展生态环境法典涉及地方性法规清理，是确保生态环境法典顺利实施、维护国家法治统一的根本要求，深入学习宣传贯彻生态环境法典及修订后的地方性法规，省司法厅将持续做好以下几个方面的工作。　　一是及时开展规章和行政规范性文件清理，维护生态环境领域法治统一。目前，省司法厅除配合省人大开展地方性法规清理外，按照省政府部署要求，已组织有关省直部门对生态环境领域的政府规章、行政规范性文件进行全面清理，提请省政府对部分省政府规章和行政规范性文件予以修改或者废止。下一步，省司法厅将严格对标生态环境法典以及新修订的地方性法规，持续强化政府规章、行政规范性文件备案审查工作，从源头上确保相关制度规定与法典保持统一，为生态环境法典落地实施提供坚实有力的制度保障。　　二是持续做好立法审查，夯实配套制度法治支撑。

B | 近年来，省司法厅持续推动完善生态环境领域法规规章制度体系建设，先后参与水、大气、土壤、固体废物、垃圾分类等污染防治立法。

C | 下一步，省司法厅将依据生态环境法典的相关规定，加快推进移动源污染防治、矿产资源管理等地方配套立法，并积极会同有关主管部门，及时梳理河南省生态环境领域的立法需求，推进地方配套法规规章的“立改废释”。　　三是深化法治宣传教育，厚植生态环境法治理念。

D | 将生态环境方面法治宣传作为全面提升全社会生态环境保护法治素养的关键举措，纳入河南省“九五”普法重点，列入年度普法要点，常态化开展生态环境法治宣传。聚焦生态环境法典重点内容、地方性法规修订内容，通过短视频、文艺节目、主题宣讲等群众喜闻乐见的形式，把“大法典”拆成“小条目”，把“纸面语”译成“家常话”，持续扩大宣传覆盖面、渗透力、影响力。完善“谁执法谁普法”普法责任清单制度，压实“谁执法谁普法”普法责任，推动相关部门把生态环境法律法规宣传嵌入执法全流程，构建部门协同、各司其职的大普法格局。

Current article:http://maigaiengsheipilongnukenjin.buzz/list_bv56/22n.html

Published on:00:00:00